AOA Dx Announced As Finalist For The Eddies, Massachusetts Innovation Network’s Signature Innovation Competition
AOA Dx is proud to announce the company has been chosen as a finalist for Massachusetts Innovation Network’ signature innovation competition, The Eddies. Finalists will have the chance to participate in this 5-month, no-cost, no-equity innovation-support program that includes individualized mentoring, strategic guidance, leadership education, and connections to resources.
AOA Dx Welcomes Women’s Health Industry Leader Surbhi Sarna as an Independent Board Member
AOA Dx is excited to announce the appointment of Surbhi Sarna as an Independent Board Member. Sarna is most recently known for becoming Y Combinator’s first-ever partner for healthcare and biotech.
Sarna is the founder and former CEO of nVision Medical, a medical device company that to date, is the only device cleared by the FDA to collect cells from the fallopian tube, the known site of the most lethal forms of ovarian cancer. nVision Medical was acquired by Boston Scientific in 2018 for $275 million.
AOA Dx Featured in The Journal of Precision Medicine
AOA Dx Inc is proud to annouce that they were featured in “The Journal of Precision Medicine, titled “Tumor Glycolipids, a New Frontier for Early Detection and Precision Medicine in Ovarian Cancer and Other Malginancies”. The paper was authored by AOA’s Chief Scientific Officer H. Uri Saragovi, PHD, AOA’s Co-Founder and Chief Business Officer Anna Milik Jeter and Samantha A. Yee, a PhD cancidate at UT San Antonio.
AOA Dx Signs Exclusive License Agreement with Professor H. Uri Saragovi to Secure a Suite of IP Related To Early Detection of Cancer Through a Novel Quantification of Tumor Ganglioside in Liquid Biopsies
AOA Dx Inc has signed an Exclusive License Agreement with Professor H. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to secure a suite of IP related to utilizing gangliosides for early cancer detection through liquid biopsies.
Chief Scientific Officer of AOA Dx Has Been Awarded $650,000 by the Canadian Institute of Health Research
AOA Dx Inc is proud to announce that their Chief Scientific Officer, Prof. H. Uri Saragovi has been awarded a $650,000 CAD grant for further development of a proprietary liquid biopsy test for early stage ovarian cancer. AOA has an exclusive license agreement to the proprietary technology. In addition to serving as AOA Dx’s Chief Scientific Officer, Prof. Saragovi is the Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University
AOA Dx Gets Y Combinator’s Backing and Raises $2.5 Million Seed Round to Develop First Non-invasive Ovarian Cancer Liquid Biopsy Diagnostic Test
AOA Dx Inc is proud to announce that they have been accepted to Y Combinator’s 2021 summer cohort and have closed a $2.5 million seed round to develop AKRIVIS GD , a liquid biopsy test that is set to revolutionize the future of ovarian cancer diagnostics. AOA Dx has been working in close collaboration with world renowned cancer researcher Professor H. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University.
AOA Dx Announces MassNextGen $87,500 Non-Dilutive Funding from Massachusetts Life Science Center
AOA Dx Inc is proud to announce that they were awarded $87,500 and access to coaching from an exclusive network of Executive Coaches through the Massachusetts Life Sciences Center’s 2021 MassNextGen Program. The program is focused on women-led early stage life science companies and is sponsored by Takeda, King Street Properties, Sanofi, Johnson & Johnson Innovation.
AOA Dx & Prof. Uri Saragovi Awarded $100,000 CAD by the Canadian Institute of Health Research for the Development of Early Stage Ovarian Cancer Diagnostic
AOA Dx Inc is proud to announce a $100,000 CAD award in collaboration with Prof. Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University for further development of a proprietary liquid biopsy for diagnosis of early stage ovarian cancer.
The funding will support ongoing development of AKRIVIS GD , a diagnostic test for ovarian cancer. The technology is based on novel method of quantifying tumor marker gangliosides in blood. This unique approach allows to diagnose ovarian cancer in early stages of the disease.
McGill University’s Clinical Innovation Competition supports the development of Prof. Uri Saragovi’s research on ovarian cancer tumor markers. AOA Dx to lead development and commercialization
AOA Dx Inc is excited to announce that they will be working with Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, to lead the development and commercialization of a simple blood test for quantitative detection of ovarian cancer tumour markers. Therapy for ovarian cancer, the “silent killer”, is 80% effective, but the five-year survival rate is 9% due to late diagnosis and recurrent disease. Early diagnosis would offer greater opportunity for curative therapy.
RQRM Grant Awarded to technology licensed by AOA Dx. Prof. Uri Saragovi and Dr. Anne-Marie Mes-Masson were awarded a grant from the RQRM for initial tumor-ganglioside screening studies to enable early detection of cancers
AOA Dx Inc is proud to announce that Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University, in collaboration with Dr. Anne-Marie Mes-Masson of the Centre hospitalier de l’Université de Montréal (CHUM) were awarded a grant from the Réseau Québécois de Recherche sur les Médicaments (RQRM). The work supported by the grant is the first of many steps demonstrating that gangliosides are an accurate and reliable marker to detect early stage cancers, and that tumor-gangliosides can be exploited for diagnostics in liquid biopsies. This award further demonstrates that world-leading scientists, such as Prof. Saragovi and Dr. Mes-Masson, are getting ever closer to accurate early-stage cancer diagnosis.